Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine Effect on SSEP During Spinal Fusion
NCT03236727Phase 3Completed
- Sponsor
- G. Papanikolaou General Hospital
- Start
- Mar 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of dexmedetomidine in spinal fusion (2 arms), sponsored by G. Papanikolaou General Hospital. Primary endpoints: Somatosensory Evoked Potential Amplitude and Somatosensory Evoked Potential Latency. Started Mar 2014; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
spinal fusion
Beyond the preview
Go deeper on NCT03236727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236727.